Introduction
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide ([@b1-or-43-04-1053]). CRC has become a critical health problem with an increase in its incidence and mortality over the past decade ([@b2-or-43-04-1053]). Despite advances in surgical resection combined with chemotherapy and radiotherapy, to the best of our knowledge, progress in treatment of CRC remains sluggish in recent years ([@b3-or-43-04-1053]). Therefore, numerous studies have attempted to illuminate the underlying mechanisms on the development of CRC and develop novel methods to improve therapeutic effects.

Catalpol, a bioactive component extracted from traditional Chinese medicine *Rehmannia glutinosa* (*Di Huang*), has various pharmacological activities ([@b4-or-43-04-1053]). Several studies indicated that catalpol has inhibitory effects on proliferation and induced apoptosis in several cancer types including human CRC ([@b3-or-43-04-1053]--[@b5-or-43-04-1053]). Our previous study also focused on the therapeutic effect of catalpol against acute liver injury via alleviation of inflammatory response ([@b6-or-43-04-1053]). However, the underlying mechanisms of catalpol in CRC treatment are still unclear, which limits the application of catalpol in CRC treatment.

microRNAs (miRs) are small noncoding RNAs which are involved in numerous biological processes. Accumulating evidence has demonstrated that miRs are aberrantly expressed in multiple human cancers and stimulate inappropriate cellular programs ([@b7-or-43-04-1053]). The antitumor and antiproliferative activities of catalpol are closely associated with aberrant versions of miRs ([@b8-or-43-04-1053]--[@b10-or-43-04-1053]), which provides insights on the interaction between catalpol and the expression of miRs. Our previous studies indicated that miR-34a has a tumor-suppressive role in human CRC and cholangiocarcinoma ([@b11-or-43-04-1053],[@b12-or-43-04-1053]); thus, we hypothesized that there may be a correlation between catalpol and miR-34a in the progression of CRC.

Recently, the roles of autophagy regulated by miRs in the progression of human cancers have been of concern ([@b13-or-43-04-1053],[@b14-or-43-04-1053]). Our previous studies demonstrated that the resistance of oxaliplatin in CRC cells was connected with miR-34a-mediated autophagy ([@b11-or-43-04-1053]). In addition, it was reported that inhibition of autophagy attenuated the anti-inflammatory effect regulated by catalpol on liver fibrosis ([@b15-or-43-04-1053]). Moreover, catalpol was revealed to suppress autophagy to prevent denervated muscular atrophy ([@b16-or-43-04-1053]). Considering the association between autophagy, miRNAs and catalpol, it was surmised that the autophagy regulated by miRNAs may be involved in mediating the functional role of catalpol. However, the exact role of miR-34a mediated by catalpol in CRC cell autophagy and apoptosis awaits to be elucidated.

Materials and methods
=====================

### Patients and tissue samples

CRC samples and adjacent normal colon tissues were obtained from 60 CRC patients (median age, 62 years; range, 47--76 years; 26 mmale and 34 mfemale patients) between January 2018 and December 2018 at the Second Affiliated Hospital of Harbin Medical University. All patients provided written informed consent according to our institutional guidelines, and the study protocol was approved by the Institutional Review Board of Harbin Medical University (KY2018-208). The samples were trimmed and snap frozen in liquid nitrogen immediately after surgical resection. The tumor stage was classified according to the 7th tumor-node-metastasis (TNM) classification of the International Union against Cancer (UICC) ([@b17-or-43-04-1053]). Data of clinical characteristics were collected from medical records.

### Animal model of azoxymethane (AOM)-induced CRC

Three-week-old male Wistar rats (40--60 g) obtained from the Animal Center of the Second Affiliated Hospital of Harbin Medical University were housed with free access to sterile food and water under a standard 12-h light/dark cycle and a controlled temperature (22±2°C) and humidity (55±5%). Animal experiments were carried out in strict accordance with the Harbin Medical University Institutional Animal Care guidelines and was approved by the Animal Research Ethics Use Committee of Harbin Medical University (KY2018-208). Thirty-six rats were randomly divided into 3 groups of 12 rats each. Animals in the experimental groups (AOM and catalpol) received AOM (15 mg/kg i.p.) and the control group received an equal volume of normal saline, once weekly for 2 weeks. Catalpol dissolved in phosphate-buffered saline (PBS; 10 mg/kg) was administered intragastrically daily from week 5 to 25. The AOM group was administered the same volume of PBS orally. Rats health and behavior were monitored every 2 days. At the end of the experiment, euthanasia by anesthesia overdose with intraperitoneal injection of sodium pentobarbital (Nembutal; 200 mg/kg body weight) was perfomed. Then colon tissue samples were obtained from each rat after decapitation was performed to confirm euthanasia ([@b6-or-43-04-1053],[@b18-or-43-04-1053]).

### Cell culture and treatment

The human colon epithelial cell line FHC obtained from the American Type Culture Collection (ATCC) was cultured in DMEM/F12 medium (GIBCO; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified 5% CO~2~ atmosphere. The human CRC cell lines HCT116, HT29, SW620 and SW480 were purchased from the Cell Bank of the Chinese Academy of Sciences and were routinely cultured using RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS. The miR-34a mimics or miR-34a inhibitor purchased from Shanghai GenePharma Co., Ltd., were transfected into the CRC cells for 48 h using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) in indicated concentrations according to the supplier\'s instructions. Rapamycin (10 nM; Cell Signaling Technology, Inc.) and 3-methyladenine (3-MA; 5 mM; Sigma-Aldrich; Merck KGaA) were added to further activate or inhibit the flux of autophagy in CRC cells as previously described ([@b12-or-43-04-1053]).

### Bioinformatics analysis and luciferase assay

Since miRNAs function by base-pairing with sequences in the 3′-UTR of their target mRNA, we used TargetScan (<http://www.targetscan.org/>) to search for potential targets of miR-34a. For luciferase reporter assay, the CRC cells were co-transfected with 80 ng mutant reporter plasmids, 10 ng pRL-TK-*Renilla*-luciferase plasmid, and sirtuin 1 (SIRT1) RNAs (20 nmol/l). Luciferase activity was assessed by quantifying the ratio of firefly luciferase activity to *Renilla* luciferase activity using the Dual-Luciferase Reporter Assay system (Promega Corporation) as previously described ([@b12-or-43-04-1053]) at 24 h after transfection.

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA or miRs were isolated from cultured cells and fresh surgical tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) or mirVana miRNA Isolation kit (Ambion; Thermo Fisher Scientific, Inc.). They were reverse-transcribed to cDNA by High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.). RT-qPCR was performed in triplicate with the Power SYBR Green (Thermo Fisher Scientific, Inc.) using the ABI StepOne system. The thermocycling parameters were as follows: 10 min at 95°C for polymerase activation followed by 40 cycles consisting of 95°C for 15 sec and 60°C for 60 sec. The expression levels of SIRT1 were normalized to β-actin, and U6 small nuclear RNA (U6) was used as the internal control for miR-34a. The 2^−∆∆Cq^ method was used to normalize the relative levels of the target genes. The details of all the primers for RT-qPCR used in this study are presented in [Table I](#tI-or-43-04-1053){ref-type="table"} ([@b19-or-43-04-1053]).

### Western blotting

Cell extracts were collected and proteins were extracted using RIPA buffer (Beyotime Institute of Biotechnology). The concentration of total protein was measured using a BCA Protein Assay Kit (Beyotime Institute of Biotechnology). Thirty µg protein lysates was electrophoresed by 12% SDS-PAGE and then transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc.). After blocking with 5% fat-free milk for 2 h, the membranes were probed with the relevant primary antibodies (SIRT1, LC3, Beclin 1, Bcl-2, Bax, cytochrome *c* and β-actin; [Table II](#tII-or-43-04-1053){ref-type="table"}) at 4°C overnight. Finally an enhanced chemiluminescence detection reagents Alexa Fluor 680 donkey anti-mouse IgG or Alexa Fluor 680 donkey anti-rabbit IgG ([Table II](#tII-or-43-04-1053){ref-type="table"}) secondary antibody was incubated with the membranes for 12 h at 4°C and visualized with an Odyssey^™^ Infrared Imaging system (LI-COR Biosciences). Densitometry was performed using Alpha Imager 2200 (Alpha Innotech Corp.). β-actin was used as a control for whole-cell lysates.

### Cell viability and cytotoxicity assay

Cell Counting Kit-8 (CCK-8; Boster Biological Technology) was used to assess cell viability as previously described ([@b11-or-43-04-1053]). The CRC cells were seeded at a density of 3×10^3^/well in 96-well plates and maintained at 37°C overnight. CCK-8 solution (10 µl) was added into each well and incubated for another 1 h. The absorbance at 450 nm was measured using a Microplate Reader (Bio-Rad Laboratories, Inc.). For the cytotoxicity assay, lactate dehydrogenase (LDH) activity in culture medium was determined using an LDH release assay kit (Boster Biological Technology).

### Evaluation of autophagy and apoptosis by flow cytometry

Cell autophagy was assessed by detecting the mono-dansylcadaverine (MDC; Sigma-Aldrich; Merck KGaA) positively stained cells using flow cytometry. Cells (10^4^) were washed with PBS and then incubated with 0.05 mmol/l MDC in PBS at 37°C for 45 min. After washing three times with PBS, the cell suspension was analyzed by flow cytometry immediately. For cell apoptosis detection, 10^4^ cells were collected in 200 ml RPMI-1640 medium without FBS. Following resuspension, approximately 10 ml Annexin V solution (BD Biosciences) was added. Fifteen min later, 300 ml medium buffer and 5 ml propidium iodide (PI; BD Biosciences) were added, and the cell suspension was analyzed by flow cytometry (BD Biosciences) immediately ([@b11-or-43-04-1053]).

### Electron microscopy

Cells from each group were harvested and fixed with 2.5% glutaraldehyde at 4°C for 2 h. The samples were suspended in PBS with 1% osmic acid. After dehydration and embedding, the ultrathin sections were prepared on uncoated copper grids with an Ultrotome (Reichert/Leica Ultracut S) and stained with 3% uranyl acetate and lead citrate for 5 min at room temperature. Images were acquired using a JEM 1230 transmission electron microscope (JEOL, Ltd.).

### Statistical analysis

Statistical analysis was carried out by SPSS version 21 (IBM Corp.) or GraphPad Prism version 5.0 (GraphPad Software, Inc.). All the data from at least three independent experiments were expressed as the mean ± standard deviation. Comparisons of quantitative data between two groups were performed using paired two-tailed Student\'s t-tests. Comparisons among three or more groups were performed by one-way ANOVA test followed by Tukey\'s test. Correlation analysis between miR-34a and SIRT1 mRNA expression levels was performed by Pearson\'s rank correlation coefficient analysis. The impact of clinical parameters was estimated by multivariate logistic regression analysis and Cox regression analysis ([Table III](#tIII-or-43-04-1053){ref-type="table"}). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### miR-34a is downregulated and SIRT1 is upregulated in CRC tissues and cell lines

The expression of miR-34a in CRC tissues was significantly decreased compared with the adjacent non-tumor tissues ([Fig. 1A](#f1-or-43-04-1053){ref-type="fig"}). SIRT1 mRNA expression was upregulated in CRC tissues compared to the adjacent normal colon tissues ([Fig. 1B](#f1-or-43-04-1053){ref-type="fig"}). Notably, the expression levels of miR-34a and SIRT1 had a significant inverse correlation ([Fig. 1C](#f1-or-43-04-1053){ref-type="fig"}) as revealed by Spearman correlation analysis. The 60 CRC patients were divided into two groups according to the median value (0.6725) of the miR-34a expression level (0.6725) in CRC tissues to further evaluate the association between the expression levels of miR-34a and the clinicopathological characteristics of CRC ([Table III](#tIII-or-43-04-1053){ref-type="table"}). The data indicated that miR-34a expression was decreased in samples with poor cell differentiation, lymphatic metastasis, high expression of carcinoembryonic antigen (CEA) and advanced clinical stages. However, age, sex, tumor size, expression of carbohydrate antigen (CA)19-9 had no association with miR-34a expression (P\>0.05). miR-34a expression was further detected in FHC and HT29, HCT116, SW480 and SW620 CRC cell lines. As revealed in [Fig. 1D](#f1-or-43-04-1053){ref-type="fig"}, the expression levels of miR-34a were significantly decreased in all the CRC cell lines compared to FHC cells. The expression levels of SIRT1 in CRC cell lines were significantly higher than that in FHC cells ([Fig. 1E](#f1-or-43-04-1053){ref-type="fig"}). HT29 and HCT116 exhibited moderate expression levels of miR-34a and SIRT1, thus these two cell lines were selected to further explore the role of the miR-34a/SIRT1 axis in the progression of CRC.

### miR-34a directly targets SIRT1 in CRC cells

Data from TargetScan (<http://www.targetscan.org/>) revealed that the 3′-UTR of SIRT1 contained the complementary site which may play a role in translational repression for the seed region of miR-34a ([Fig. 2A](#f2-or-43-04-1053){ref-type="fig"}). A dual luciferase assay was conducted in HT29 and HCT116 cells. As revealed in [Fig. 2B](#f2-or-43-04-1053){ref-type="fig"}, miR-34a mimic transfection (PGL3′-UTR WT) decreased luciferase activity compared to the control group. Additionally, transfection with the mutated 3′-UTR (PGL3′-UTR MUT) of the SIRT1 gene, revealed no significant difference in luciferase activities between the miR-34a mimic transfection and the control groups. Moreover, compared to the normal control group, miR-34a mimic transfection and miR-34a inhibitor successfully increased and decreased, respectively, the endogenous miR-34a expression levels in CRC cells ([Fig. 2C](#f2-or-43-04-1053){ref-type="fig"}). Results of western blotting revealed that the transfection with the miR-34a mimics decreased SIRT1 expression while transfection with the miR-34a inhibitor promoted SIRT1 expression at the protein level in CRC cells ([Fig. 2D](#f2-or-43-04-1053){ref-type="fig"}). These data indicated that SIRT1 was one of the direct targets of miR-34a in CRC cells.

### Catalpol suppresses autophagy and induces apoptosis through the miR-34a/SIRT1 axis in CRC cell lines

The effects of catalpol on CRC cell viability and cytotoxicity were initially evaluated *in vitro*. CRC cell viability was significantly decreased by 30--50 µM catalpol treatment compared to the control group ([Fig. 3A](#f3-or-43-04-1053){ref-type="fig"}). Cytotoxicity was revealed at a concentration of 40 µM ([Fig. 3B](#f3-or-43-04-1053){ref-type="fig"}). Thus, 30 µM was used in the following experiments. Whether catalpol significantly inhibited autophagy in CRC cells was next investigated. MDC-positively stained CRC cells were significantly decreased by catalpol treatment ([Fig. 3C](#f3-or-43-04-1053){ref-type="fig"}). Consistent with the flow cytometric results, [Fig. 3D](#f3-or-43-04-1053){ref-type="fig"} reveals the decreased autophagosomes associated with catalpol treatment in CRC cells. Compared with the normal controls, expression of autophagy-related protein Beclin 1 and LC3-II (also referred as MAPLC3β) was significantly downregulated by catalpol ([Fig. 3G](#f3-or-43-04-1053){ref-type="fig"}). Induction of apoptosis of CRC cells by catalpol was demonstrated by flow cytometry ([Fig. 3E](#f3-or-43-04-1053){ref-type="fig"}) and Bax, cytochrome *c* expression levels were increased, while Bcl-2 protein expression levels were reduced ([Fig. 3G](#f3-or-43-04-1053){ref-type="fig"}). Consistent with previous studies ([@b8-or-43-04-1053]--[@b10-or-43-04-1053]), expression of miR-34a in CRC cells was markedly upregulated by catalpol treatment compared to control cells ([Fig. 3F](#f3-or-43-04-1053){ref-type="fig"}). As anticipated, expression of SIRT1 in both HT29 and HCT116 cells was downregulated by catalpol ([Fig. 3G](#f3-or-43-04-1053){ref-type="fig"}). These results indicated that suppression of autophagy and induction of apoptosis of CRC cells by catalpol may be partly achieved through the miR-34a/SIRT1 axis.

### Catalpol-regulated autophagy is involved in mediating apoptosis in CRC cells

To address whether catalpol regulated autophagy-modulated apoptosis of CRC cells, the CRC cells were subjected to catalpol with or without 3-MA and rapamycin treatment. The results revealed that catalpol inhibited autophagy and induced apoptosis of CRC cells, as indicated by decreased MDC-positive cells ([Fig. 4A](#f4-or-43-04-1053){ref-type="fig"}) and autophagosomes ([Fig. 4B](#f4-or-43-04-1053){ref-type="fig"}); decreased expression levels of LC3-II, Beclin 1 and Bcl-2; and higher expression levels of Bax and cytochrome *c* ([Fig. 4D](#f4-or-43-04-1053){ref-type="fig"}) as well as the apoptotic rate ([Fig. 4C](#f4-or-43-04-1053){ref-type="fig"}). 3-MA significantly suppressed autophagy and induced apoptosis of CRC cells while rapamycin activated autophagy but had no effect on apoptosis in CRC cells, as revealed by increased MDC-positive cells ([Fig. 4A](#f4-or-43-04-1053){ref-type="fig"}) and autophagosomes ([Fig. 4B](#f4-or-43-04-1053){ref-type="fig"}) and higher expression of autophagy-related proteins ([Fig. 4D](#f4-or-43-04-1053){ref-type="fig"}). In addition, 3-MA combined with catalpol did not affect either autophagy activity or apoptosis of CRC cells as compared with treatment with catalpol alone. However, compared with treatment with catalpol alone, rapamycin in combination with catalpol attenuated the inhibitory effect on autophagy and induced apoptosis of CRC cells ([Fig. 4](#f4-or-43-04-1053){ref-type="fig"}). These results strongly indicated that inhibition of autophagy by catalpol may exert an accelerated effect on apoptosis of CRC cells.

### The miR-34a/SIRT1 pathway participates in regulating catalpol-suppressed CRC cell autophagy and induces apoptosis

miR-34a and catalpol have been demonstrated as key regulators of autophagy ([@b11-or-43-04-1053],[@b15-or-43-04-1053]); thus, it was investigated whether miR-34a was involved in mediating catalpol-regulated autophagy and apoptosis of CRC cells. Both the cell lines were treated by catalpol and transfected with miR-34a mimics or inhibitors. The number of MDC-positive cells detected by flow cytometry ([Fig. 5A](#f5-or-43-04-1053){ref-type="fig"}) and autophagosomes detected by electron microscopy ([Fig. 5B](#f5-or-43-04-1053){ref-type="fig"}) were significantly decreased compared to the controls. Western blotting revealed decreased expression of SIRT1, LC3-II, Beclin 1 and Bcl-2, and higher expression of Bax and cytochrome *c* ([Fig. 5D](#f5-or-43-04-1053){ref-type="fig"}) in CRC cells in the catalpol treatment and miR-34a mimics transfection groups compared to the control group. Similarly, the apoptotic rate was significantly increased in both cell lines by treatment with catalpol or miR-34a mimics compared to the control group ([Fig. 5C](#f5-or-43-04-1053){ref-type="fig"}). The level of autophagy was enhanced but apoptosis was not weakened in both HT29 and HCT116 cell lines by the miR-34a inhibitor, since the results revealed increased MDC-positive cells ([Fig. 5A](#f5-or-43-04-1053){ref-type="fig"}) and autophagosomes ([Fig. 5B](#f5-or-43-04-1053){ref-type="fig"}), along with increased SIRT1, LC3-II and Beclin 1 protein expression levels ([Fig. 5D](#f5-or-43-04-1053){ref-type="fig"}). The effect on CRC cell apoptosis was not significant compared to the control group ([Fig. 5C and D](#f5-or-43-04-1053){ref-type="fig"}). Treatment with catalpol in combination with miR-34a mimic had no significant effect on autophagy flux or apoptosis compared with catalpol alone in HT29 and HCT116 cells ([Fig. 5](#f5-or-43-04-1053){ref-type="fig"}). Compared with catalpol alone, the inhibitory effect of autophagy and induction of apoptosis were impaired by catalpol in combination with miR-34a inhibitor in CRC cells, as indicated by increased MDC-positive cells ([Fig. 5A](#f5-or-43-04-1053){ref-type="fig"}) and autophagosomes ([Fig. 5B](#f5-or-43-04-1053){ref-type="fig"}), increased expression of SIRT1, LC3-II, Beclin 1 and Bcl-2, and decreased expression of Bax and cytochrome *c* ([Fig. 5D](#f5-or-43-04-1053){ref-type="fig"}) in CRC cells. Moreover, the inhibitory effect on apoptosis was significantly reduced in both HT29 and HCT116 cell lines compared to catalpol treatment alone ([Fig. 5C](#f5-or-43-04-1053){ref-type="fig"}). These data indicated that the miR-34a/SIRT1 axis at least partly participated in mediating catalpol-suppressed autophagy and catalpol-induced apoptosis of CRC cells.

### Catalpol inhibits tumorigenesis through regulation of the miR-34a/SIRT1 pathway in a rat model

The AOM-induced CRC rat model was used to evaluate the chemopreventive effect and toxicity of catalpol *in vivo*. First, percentage weight gain among each group was observed, however the differences were not significant (data not shown). As revealed in [Fig. 6A](#f6-or-43-04-1053){ref-type="fig"}, catalpol intervention markedly prevented the formation of colon tumors. All rats treated with AOM developed preneoplastic aberrant crypt foci (ACF) ([Fig. 6B](#f6-or-43-04-1053){ref-type="fig"}). The catalpol group had a significantly decreased number of ACFs with ≤4 crypts as well as total ACF compared to the AOM group ([Fig. 6B](#f6-or-43-04-1053){ref-type="fig"}). No significant difference was revealed in the number of ACFs containing \>5 crypts among the groups ([Fig. 6B](#f6-or-43-04-1053){ref-type="fig"}). To determine the potential mechanism of catalpol *in vivo*, miR-34a and SIRT1 mRNA expression levels in colon tissues from each group were examined by RT-qPCR. Consistent with the results *in vitro*, expression of miR-34a was significantly decreased in the AOM-treated group compared to the control group, and catalpol treatment promoted the expression of miR-34a compared to AOM treatment ([Fig. 6C](#f6-or-43-04-1053){ref-type="fig"}). The expression of SIRT1 mRNA was significantly upregulated by treatment with AOM compared to the control while treatment with catalpol in combination with AOM inhibited the promoting effect on the expression of SIRT1 compared to AOM treatment alone ([Fig. 6D](#f6-or-43-04-1053){ref-type="fig"}). These results provided evidence that the catalpol-mediated miR-34a/SIRT1 pathway was involved in inhibition of malignant behavior *in vivo*.

Discussion
==========

Catalpol is one of the main active ingredients of *R. glutinosa* (*Di Huang*) which has been revealed to have antitumor effects on various of human cancers ([@b5-or-43-04-1053],[@b8-or-43-04-1053]--[@b10-or-43-04-1053]). Recently, the inhibited effect on inflammation and tumor angiogenesis of catalpol in CRC cells was revealed and catalpol was considered as a potential candidate compound for treating CRC ([@b3-or-43-04-1053],[@b10-or-43-04-1053],[@b20-or-43-04-1053]). Significant changes in the miRNA expression profiles were observed in cancer cells after catalpol treatment ([@b8-or-43-04-1053]--[@b10-or-43-04-1053],[@b21-or-43-04-1053]). Moreover, the present findings indicated that miR-34a played a tumor-suppressive role during progression of human CRC and cholangiocarcinoma ([@b11-or-43-04-1053],[@b12-or-43-04-1053]). Thus, miR-34a was selected as a candidate gene for catalpol in the present study. The present research revealed that miR-34a was aberrantly downregulated in most of human CRC tissues and all the CRC cell lines. Since miRNAs exert physiological functions by directly modulating their target mRNA expression, bioinformatics analysis was performed to predict if SIRT1 may be one of the potential targets of miR-34a. SIRT1 is a class III nuclear deacetylase that can mediate genetic programs by modifying histones and transcription factors ([@b22-or-43-04-1053]). SIRT1 is reported to inactivate p53 by deacetylating a critical lysine residue, and blocking SIRT1 may lead to the activation of the p53 pathway and suppress the progression of human cancers including CRC ([@b23-or-43-04-1053]). Moreover, miR-34a could bind the site within the 3′-UTR of SIRT1 to silence the mRNA as revealed in a previous study ([@b24-or-43-04-1053]). Consistent with previous research, ectopic expression of miR-34a interposed SIRT1 protein expression in CRC cell lines, and miR-34a may be a tumor-suppressor and function by directly inhibiting SIRT1 expression in the progression of CRC.

Mounting evidence has revealed that catalpol has inhibitory effects on proliferation and inducing effects on apoptosis in several types of human malignancies ([@b8-or-43-04-1053]--[@b10-or-43-04-1053],[@b21-or-43-04-1053]). Moreover, catalpol was revealed to inhibit autophagy and decrease apoptosis via the mammalian target of rapamycin pathway in denervated muscular atrophy ([@b16-or-43-04-1053]). In addition, it was reported that resistance of autophagy attenuated the catalpol-induced anti-inflammatory effect on liver fibrosis ([@b15-or-43-04-1053]). In the present study, it was revealed that 30--50 µM catalpol suppressed cell viability and 40 µM catalpol resulted in toxicity in CRC cells. Thus, 30 µM was used in the subsequent experiments. As documented previously, modest autophagy may protect cells from apoptosis under different conditions ([@b11-or-43-04-1053],[@b25-or-43-04-1053]). The present data indicated that CRC cell autophagy was significantly inhibited and apoptosis was induced by catalpol treatment. Moreover, it was revealed that catalpol upregulated miR-34a expression and suppressed SIRT1 expression in CRC cells. Catalpol has been revealed to target multiple signaling pathways, including Bcl-2/Bax, JNK, NF-κB to exert its pharmacological effects ([@b26-or-43-04-1053],[@b27-or-43-04-1053]). Thus, the antitumor effects and the potential mechanisms underlying the catalpol-mediatied miR-34a/SIRT1 axis may be regulated by complex signaling pathways. The present study indicated that the miR-34a/SIRT1 axis was likely involved in regulating catalpol suppression of autophagy and induction of apoptosis in CRC cells, however, more studies are required in the future.

To date, there is wide recognition that autophagy plays a dual role in regulating the fate of cancer cells ([@b28-or-43-04-1053]). Although increasing evidence has focused on the association between autophagy and progression of malignant tumors, it is far from being clarified. The present study indicated that catalpol and 3-MA attenuated activation of autophagy and induced apoptosis of CRC cells. In addition, 3-MA in combination with catalpol did not show any effect on autophagy or apoptosis of CRC cells. Notably, rapamycin impaired the promoting effect of catalpol on CRC cell apoptosis. Therefore, it was suggested that catalpol may induce CRC cell apoptosis by suppressing autophagy.

To determine whether miR-34a participated in mediating catalpol-regulated autophagy and apoptosis, CRC cells were treated by catalpol and concurrent promotion or silencing of miR-34a expression. It was confirmed that both catalpol and miR-34a overexpression antagonized cell autophagy and promoted apoptosis of CRC cells. The autophagy was aggravated but apoptosis was not restrained when miR-34a was exogenously inhibited. Combination treatment with catalpol and miR-34a mimic revealed no effect on autophagy or apoptosis in CRC cells. Moreover, the antitumor effects of catalpol were neutralized by concurrent silencing of miR-34a expression. Previous studies indicated that catalpol administration significantly alleviated symptoms in a rat colitis model ([@b21-or-43-04-1053],[@b29-or-43-04-1053]). The present results indicated that there was no significant weight gain in any of the experimental groups, which may be because the experiment period was not long enough. However, all rats treated with AOM developed preneoplastic ACF in the colon. Catalpol treatment impaired the carcinogenic effects of AOM. Moreover, as was anticipated, catalpol promoted the expression of miR-34a and inhibited the expression of SIRT1 in the colon of rats. Conversely, Xiong *et al* reported that activation of SIRT1 by catalpol attenuated infiltration of inflammatory cells, cytokine profiles, oxidative responses, and epithelial cell apoptosis in colitis rats ([@b21-or-43-04-1053]). The appearance of this discrepancy in SIRT1 expression by catalpol treatment may be due to the totally different diseases and AOM-induced stages as well as the different cell lines used in *in vitro* investigations. Thus, it was speculated that catalpol may induce apoptosis and inhibit autophagy at least partly by upregulating miR-34a, along with suppression of SIRT1 expression ([Fig. 7](#f7-or-43-04-1053){ref-type="fig"}).

In summary, it was demonstrated that miR-34a functioned as an antioncogene in human CRC, which was at least in part through the suppression of SIRT1 expression. Aberrantly downregulated expression of miR-34a in CRC patients was correlated with adverse clinical characteristics. In addition, cell autophagy was suppressed while apoptosis was induced by catalpol treatment in human CRC cells. Catalpol-regulated autophagy was demonstrated to participate in mediating apoptosis in CRC cells. Furthermore, miR-34a was upregulated by catalpol treatment and catalpol may function by modulating the miR-34a/SIRT1 axis, which at least partly provides an insight into the mechanisms underlying catalpol treatment and may be considered as a novel therapeutic target for CRC.
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###### 

miR-34a is downregulated and SIRT1 is upregulated in CRC tissues and cell lines. (A) RT-qPCR was performed to examine downregulated miR-34a expression in 60 CRC samples (\*P\<0.05). (B) RT-qPCR was performed to examine upregulated SIRT1 mRNA expression in CRC specimens compared to the adjacent non-tumor tissues (\*P\<0.05). (C) Inverse correlation between miR-34a and SIRT1 expression was determined by Spearman\'s rank correlation coefficient analysis (R=−0.241, P=0.008). (D) RT-qPCR revealed downregulated expression of miR-34a in CRC cell lines (SW480, HCT116, HT29 and SW620) compared to FHC cells (\*\*\*P\<0.001). (E) RT-qPCR revealed overexpression of SIRT1 mRNA in CRC cell lines compared to FHC cells (\*\*\*P\<0.001). \*P\<0.05 indicated a significant difference vs. the control group; \*\*\*P\<0.001 indicated a significant difference vs. the FHC cells. miR, microRNA; SIRT1, sirtuin 1; CRC, colorectal cancer.
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###### 

SIRT1 is a direct miR-34a target in CRC cell lines. (A) Data from TargetScan revealed the miR-34a binding site in the 3′-UTR of SIRT1. (B) Luciferase reporter assay revealed a reduction in luciferase activity of WT SIRT1 3′-UTR by transfection with miR-34a mimic in HT29 and HCT116 cells (\*\*\*P\<0.001). (C) RT-qPCR analysis of the expression of miR-34a in CRC cells by miR-34a mimic or inhibitor transfection (\*\*\*P\<0.001). (D) SIRT1 protein expression was examined by western blotting (\*P\<0.05 and \*\*P\<0.01 indicates a significant difference vs. the control group). SIRT1, sirtuin 1; miR, microRNA; CRC, colorectal cancer; WT, wild-type.
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###### 

Catalpol reduces cell viability, suppresses autophagy and induces apoptosis through the miR-34a/SIRT1 axis *in vitro*. (A) The inhibited effect of catalpol on CRC cell viability determined by CCK-8 analysis (\*\*\*P\<0.001). (B) LDH activity assay was used to examined the toxicity of catalpol on HT29 and HCT116 cells (\*\*\*P\<0.001). (C) Autophagy of CRC cells was determined using flow cytometry (\*\*P\<0.01 and \*\*\*P\<0.001). (D) Autophagic vacuole formation was revealed by representative electron micrographs in CRC cell lines. The arrows indicate the autophagosomes. Catalpol reduces cell viability, suppresses autophagy and induces apoptosis through the miR-34a/SIRT1 axis *in vitro*. (E) Analysis of apoptosis by flow cytometry in HT29 and HCT116 cells (\*\*\*P\<0.001). (F) Expression of miR-34a was determined by RT-qPCR (\*\*\*P\<0.001). (G) Western blotting was performed to detect SIRT1 and autophagy, and apoptosis-related proteins in CRC cells (\*\*P\<0.01 and \*\*\*P\<0.001 indicates a significant difference vs. the normal control group). miR, microRNA; SIRT1, sirtuin 1; CRC, colorectal cancer; LDH, lactate dehydrogenase; CCK-8, Cell Counting Kit-8.
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###### 

Inhibition of autophagy regulated by catalpol contributes to apoptosis in CRC cells. (A) CRC cells were exposed to 30 µM catalpol for 24 h and treated with or without 3-MA and rapamycin, and then flow cytometry was used to detect the autophagic levels (\*\*\*P\<0.001 and ^\#\#\#^P\<0.001). (B) Autophagic vacuole formation was revealed by representative electron micrographs in CRC cell lines. The arrows indicate the autophagosomes. (C) Apoptosis was analyzed by flow cytometry in CRC cells after various treatments (\*\*\*P\<0.001 and ^\#\#\#^P\<0.001). (D) Western blotting revealed the expression of SIRT1, LC3II, Beclin 1, Bcl-2, Bax, and cytochrome c in HT29 and HCT116 cells. β-Actin was used as a loading control. Quantitation of the results was performed (\*\*\*P\<0.001 indicates a significant difference vs. the normal control group; ^\#^P\<0.05, ^\#\#^P\<0.01 and ^\#\#\#^P\<0.001 indicates a significant difference vs. the group treated with catalpol). CRC, colorectal cancer; SIRT1, sirtuin 1; 3-MA, 3-methyladenine.
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###### 

The miR-34a/SIRT1 axis participates in regulating catalpol-suppressed CRC cell autophagy and induces apoptosis. (A) HT29 and HCT116 cells were treated with 30 µM catalpol for 24 h and in combination with miR-34a mimic or inhibitor, and then flow cytometry was used to examine autophagic levels (\*\*\*P\<0.001 and ^\#\#\#^P\<0.001). (B) Autophagic vacuole formation was revealed by representative electron micrographs in CRC cell lines. The arrows indicate the autophagosomes. (C) The CRC cell apoptotic rate was analyzed by flow cytometry (\*\*\*P\<0.001 and ^\#\#\#^P\<0.001). (D) Western blotting revealed the expression of SIRT1, LC3, Beclin 1, Bcl-2, Bax, and cytochrome *c* in HT29 and HCT116 cells (\*P\<0.05 and \*\*\*P\<0.001 indicates a significant difference vs. the normal control group; ^\#^P\<0.05, ^\#\#^P\<0.01 and ^\#\#\#^P\<0.001 indicates a significant difference vs. the group treated with catalpol). miR, microRNA; SIRT1, sirtuin 1; CRC, colorectal cancer.

![](OR-43-04-1053-g20)

![](OR-43-04-1053-g21)

![](OR-43-04-1053-g22)

![](OR-43-04-1053-g23)

###### 

Catalpol inhibits tumorigenesis in a rat model of AOM-induced CRC by regulating the miR-34a/SIRT1 axis. (A) Catalpol treatment suppressed the formation of colon tumors. (B) Number of ACFs with ≤4 crypts from the colon of rats (\*\*\*P\<0.001 and ^\#\#\#^P\<0.001). Number of ACFs with \>5 crypts in the entire colon (P\>0.05). Total number of ACFs in the entire colon (\*\*\*P\<0.001 and ^\#\#\#^P\<0.001). (C) Expression of miR-34a in colon samples determined by RT-qPCR (\*\*P\<0.01 and ^\#^P\<0.05). (D) SIRT1 mRNA expression levels in the colon samples determined by RT-qPCR (\*\*P\<0.01, ^\#^P\<0.05) (\*\*P\<0.01 and \*\*\*P\<0.001 indicates a significant difference vs. the control group; ^\#^P\<0.05 and ^\#\#\#^P\<0.001 indicates a significant difference vs. the group treated with AOM). AOM, azoxymethane; CRC, colorectal cancer; miR, microRNA; ACF, aberrant crypt foci; SIRT1, sirtuin 1.
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![Catalpol-inhibited autophagy is involved in inducing CRC cell apoptosis by mediating the miR-34a/SIRT1 axis. CRC, colorectal cancer; miR, microRNA; ACF, aberrant crypt foci; SIRT1, sirtuin 1.](OR-43-04-1053-g28){#f7-or-43-04-1053}

###### 

Primers used for RT-qPCR.

  Primer name   Primer sequence: 5′-3′
  ------------- ----------------------------
  SIRT1         F: CCCAGAACATAGACACGCTGGA
                R: ATCAGCTGGGCACCTAGGACA
  β-actin       F: ATGTTGAGACCTTCAACACC
                R: AGGTAGTCAGTCAGGTCCCGGCC
  miR-34a       F: TGGTGTCGTGGAGTCG
                R: GGCATCTCTCGCTTCATCTT
  U6            F: CTCGCTTCGGCAGCACA
                R: AACGCTTCACGAATTTGCGT

SIRT1, sirtuin 1; miR, microRNA; F, forward; R, reverse.

###### 

Antibodies used for western blotting.

  Antibody                                               Manufacturer                                          Species   Dilution
  ------------------------------------------------------ ----------------------------------------------------- --------- ----------
  SIRT1                                                  cat. no. sc-135792 (Santa Cruz Biotechnology, Inc.)   Mouse     1:500
  LC3-II (MAPLC3β)                                       cat. no. sc-28266 (Santa Cruz Biotechnology, Inc.)    Rabbit    1:500
  Beclin 1                                               cat. no. sc-11427 (Santa Cruz Biotechnology, Inc.)    Rabbit    1:500
  Bcl-2                                                  cat. no. sc-7382 (Santa Cruz Biotechnology, Inc.)     Mouse     1:200
  Bax                                                    cat. no. sc-526 (Santa Cruz Biotechnology, Inc.)      Mouse     1:200
  Cytochrome *c*                                         cat. no. sc-13156 (Santa Cruz Biotechnology, Inc.)    Mouse     1:200
  β-actin                                                cat. no. sc-69879 (Santa Cruz Biotechnology, Inc.)    Mouse     1:500
  Alexa Fluor 680 donkey anti-mouse IgG anti-mouse IgG   A10038 (Thermo Fisher Scientific, Inc.)               Donkey    1:5,000
  Alexa Fluor 680 donkey anti-rabbit IgG                 A10043 (Thermo Fisher Scientific, Inc.)               Donkey    1:5,000

SIRT1, sirtuin 1.

###### 

Relationship between miR-34a expression and clinicopathological features in CRC patients.

                                   miR-34a        
  --------------------------- ---- --------- ---- ---------
  Age (years)                                     0.603
    \<60                      27   14        13   
    ≥60                       33   16        17   
  Sex                                             0.397
    Male                      26   14        12   
    Female                    34   16        18   
  Tumor size (cm)                                 0.094
    \<5                       36   19        17   
    ≥5                        24   11        13   
  Differentiation                                 \<0.001
    Well/moderate             20   2         18   
    Poor                      40   28        12   
  Lymphatic node metastasis                       \<0.001
    Present                   43   28        15   
    Absent                    17   2         15   
  Clinical stages                                 \<0.001
    I/II                      17   2         15   
    III/IV                    43   28        15   
  CA199 level (U/ml)                              0.500
    \<37                      31   15        16   
    ≥37                       29   15        14   
  CEA level (ng/ml)                               \<0.001
    \<5                       16   2         14   
    ≥5                        44   28        16   

The median value of miR-34a expression level in CRC patients was 0.6725. P\<0.05 is considered to indicate a statistically significant difference. CRC, colorectal cancer; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.
